This article is more than 5 years old. Information may no longer be current.

Pain, bruising similar using hyaluronic acid with, without lidocaine, epinephrine for perioral lines

Results of a blinded, split-face study showed no significant differences in bruising or pain among patients treated with hyaluronic acid alone, hyaluronic acid with lidocaine or hyaluronic acid with lidocaine and epinephrine for perioral lines.

Within the study, researchers divided 30 patients into groups of 10, with one group receiving a 1-mL injection of cohesive polydensified matrix with hyaluronic acid (CPMHA) in the perioral lines on one side of the face and a 1-mL injection of CPMHA with lidocaine and epinephrine on the other side of the face. Patients in the second group received a 1-mL injection of CPMHA on one side of the face and a 1-mL injection of CPMHA with lidocaine on the other, and patients in a third group received 1 mL of CPMHA with lidocaine on one side of the face and 1 mL of CPMHA with lidocaine and epinephrine on the other side of the face. Bruising and pain were analyzed by the patients, the treating investigator and a blinded investigator during the course of three visits.

On day 1 postoperatively, the bruising was most pronounced; however, the bruising decreased by more than 50% by day 7. In all of the patients, bruising resolved by day 14, according to the researchers. Additionally, the researchers noted bruising scores were similar across cohorts regardless of the mixture used.

Pain scores were recorded by the patients immediately following both injections on either side of the face. The differences in perceived pain were similar across all three cohorts.

The researchers found no statistically significant differences in pain and bruising when lidocaine or lidocaine and epinephrine were added to the CPMHA injections.

Disclosures: Moradi is a paid speaker, consultant and advisory board member for Allergan, Galderma Laboratories, SkinMedica and Merz North America. Please see the full study for a list of all other authors’ relevant financial disclosures.